Descovy: New Indication for HIV Pre-exposure Prophylaxis
Jace Swingle, Madison Grilliot
Human Immunodeficiency Virus (HIV) is a viral infection spread by contact with bodily fluids. If untreated, it results in severe immunodeficiency and ultimately death. In the 1990’s, treatments to enhance the duration and quality of life were developed, and more recently, treatments have been designed to help prevent HIV infection. Currently, there is no cure for HIV infection; therefore, prevention is key to maintaining a healthy lifestyle in high risk patients. This article features a new indication for Descovy (emtricitabine and tenofovir alafenamide), which was approved by the FDA for HIV pre-exposure prophylaxis (PrEP).